Business Description
Tryptamine Therapeutics Ltd
ISIN : AU0000331993
Share Class Description:
TYPTF: Ordinary SharesDescription
Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.8 | |||||
| Debt-to-EBITDA | -0.3 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 5.95 | |||||
| Beneish M-Score | -3.47 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 28.7 | |||||
| 3-Year EPS without NRI Growth Rate | 9.8 | |||||
| 3-Year FCF Growth Rate | 32.9 | |||||
| 3-Year Book Growth Rate | -41.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.16 | |||||
| 9-Day RSI | 42.99 | |||||
| 14-Day RSI | 45.1 | |||||
| 3-1 Month Momentum % | -55.2 | |||||
| 6-1 Month Momentum % | -25.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.55 | |||||
| Quick Ratio | 4.55 | |||||
| Cash Ratio | 2.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -59.7 | |||||
| Shareholder Yield % | -5.13 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1549.6 | |||||
| Net Margin % | -1151.86 | |||||
| FCF Margin % | -562.57 | |||||
| ROE % | -115.84 | |||||
| ROA % | -96.11 | |||||
| ROIC % | -408.23 | |||||
| 3-Year ROIIC % | 2784.21 | |||||
| ROC (Joel Greenblatt) % | -658.1 | |||||
| ROCE % | -115.25 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4.88 | |||||
| PB Ratio | 13 | |||||
| EV-to-EBIT | -22.04 | |||||
| EV-to-EBITDA | -79.35 | |||||
| EV-to-Revenue | 194.79 | |||||
| EV-to-FCF | -9.64 | |||||
| Price-to-Net-Current-Asset-Value | 1.12 | |||||
| Earnings Yield (Greenblatt) % | -4.54 | |||||
| FCF Yield % | -2.87 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:TYPTF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tryptamine Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.171 | ||
| EPS (TTM) ($) | -0.025 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 45.1 | ||
| 14-Day ATR ($) | 0.00429 | ||
| 20-Day SMA ($) | 0.01436 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 0.0007 - 0.0385 | ||
| Shares Outstanding (Mil) | 1,276.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tryptamine Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tryptamine Therapeutics Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Tryptamine Therapeutics Ltd Frequently Asked Questions
What is Tryptamine Therapeutics Ltd(TYPTF)'s stock price today?
The current price of TYPTF is $0.01. The 52 week high of TYPTF is $0.04 and 52 week low is $0.00.
When is next earnings date of Tryptamine Therapeutics Ltd(TYPTF)?
The next earnings date of Tryptamine Therapeutics Ltd(TYPTF) is .
Does Tryptamine Therapeutics Ltd(TYPTF) pay dividends? If so, how much?
Tryptamine Therapeutics Ltd(TYPTF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers